1211596-82-5

Basic information

• Product Name: 4-bromo-1H-indole-7-carboxamide
• Synonyms: 4-bromo-1H-indole-7-carboxamide;1H-Indole-7-carboxaMide, 4-broMo-
• CAS NO: 1211596-82-5
• Molecular Formula: C9H7BrN2O
• Molecular Weight: 239.06868
• Mol File: 1211596-82-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-bromo-1H-indole-7-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-1H-indole-7-carboxamide(1211596-82-5)
• EPA Substance Registry System: 4-bromo-1H-indole-7-carboxamide(1211596-82-5)

Safety Data

• Hazardous Substances Data: 1211596-82-5(Hazardous Substances Data)

Usage

General Description

4-bromo-1H-indole-7-carboxamide is a chemical compound with the molecular formula C9H8BrN2O. It is a derivative of indole, which is a heterocyclic aromatic organic compound. 4-bromo-1H-indole-7-carboxamide is commonly used in the pharmaceutical industry and has shown potential in the development of anti-cancer and anti-inflammatory drugs. Its bromine substitution makes it a valuable intermediate for the synthesis of various pharmaceutical compounds. It is also used as a building block for the synthesis of various heterocyclic compounds with potential pharmacological properties. Additionally, it has been studied for its potential use in photonic applications due to its fluorescence properties.

Upstream product

• 604788-34-3 4,7-dibromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indole 
• 1224724-39-3 methyl 4-bromo-1H-indole-7-carboxylate 
• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 1167055-46-0 4-bromo-1H-indole-7-carbonitrile 
• 1211594-25-0 4-bromo-1H-indole-7-carboxylic acid 
• 126811-31-2 4,7-Dibromo-1H-indole 
• 3460-18-2 1,4-dibromo-2-nitrobenzene 

Downstream Products

• 1309980-17-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-7-carboxamide 

Relevant articles and documents

Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series

Incorporation of a suitably-placed electrophilic group transformed a series of reversible BTK inhibitors based on carbazole-1-carboxamide and tetrahydrocarbazole-1-carboxamide into potent, irreversible inhibitors. Removal of one ring from the core of these compounds provided a potent irreversible series of 2,3-dimethylindole-7-carboxamides having excellent potency and improved selectivity, with the additional advantages of reduced lipophilicity and molecular weight.

PRIMARY CARBOXAMIDES AS BTK INHIBITORS

The invention provides carboxamide compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions, including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing spondylitis, interstitial cystitis, asthma, systemic lupus erythematosus, lupus nephritis, B cell chronic lymphocytic lymphoma, multiple sclerosis, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's lymphoma, activated B-celllike diffuse large B-cell, lymphoma, multiple myeloma, diffuse large B-celllymphoma, follicular lymphoma, hairy cell leukemia or Lymphoblastic lymphoma.